Narayan and Nishtala reported the Medicines Comorbidity Index (MCI) for use in a pharmacy claims database. It can help to measure multimorbidity in older adults. The authors are from the University of Otago in New Zealand.
Target population: age >= 65 years
Number of conditions: 20
Condition |
Points |
cancer |
3 |
HIV/AIDS |
3 |
diabetes |
2 |
end-stage renal disease |
2 |
epilepsy |
2 |
respiratory illness |
2 |
dementia |
1 |
dyslipidemia |
1 |
glaucoma |
1 |
gout |
1 |
heart disease |
1 |
hepatitis B |
1 |
hepatitis C |
1 |
hypertension |
1 |
hepatic cirrhosis |
1 |
osteoporosis |
1 |
Parkinson's disease |
1 |
peptic ulcer |
1 |
rheumatoid arthritis |
1 |
thyroid disorder |
1 |
Condition |
Drugs |
cancer |
alkylating agents, anthracyclines, anti-androgens, anti-lymphocyte monoclonal antibodies, antimetabolites, aromatase inhibitors, gonadotropin-releasing hormone agonists, other cytotoxic and non-cytotoxic antineoplastics, platinum compounds, selective estrogen receptor modulators, taxanes, thalidomide analogues, topoisomerase I inhibitors, tyrosine kinase inhibitors, Vinca alkaloids |
HIV/AIDS |
HIV-protease inhibitors, integrase inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, other antiretrovirals |
diabetes |
acarbose, biguanides, insulins, sulfonylureas, thiazolidinediones |
end-stage renal disease |
calcium polystyrene sulfonate, epoetin alfa, epoetin beta, polystyrene sulfonate sodium |
epilepsy |
barbiturates, benzodiazepines, carbamazepine, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, pregabalin, sulthiame, topiramate, valproate, vigabatrin |
respiratory illness |
antimuscarinic bronchodilators, beta-2 agonists, cromone, inhaled corticosteroids, leukotriene receptor antagonists, xanthines |
dementia |
anticholinesterase |
dyslipidemia |
bile acid-binding resins, fibrates, other drugs for dyslipidemia, statins |
glaucoma |
acetazolamide, alpha2 agonists, beta blockers (ophthalmic), carbonic anhydrase inhibitors, mannitol, pilocarpine, prostaglandin analogues |
gout |
colchicine, probenecid, xanthine oxidase inhibitor |
heart disease |
aldosterone antagonists, angiotensin-converting enzyme inhibitors, antiplatelets agents, anticoagulation, beta blockers, calcium channel blockers, loop diuretics, nicorandil, nitrates, perhexilline |
hepatitis B |
adefovir, entecavir, peginterferon alfa |
hepatitis C |
HCV protease inhibitors, ribavirin, ribavirin with peginterferone alfa |
hypertension |
clonidine, diazoxide, hydralazine, methyldopa, minoxidil, potassium-sparing diuretic, sartans, selective alpha blockers, sodium nitroprusside, thiazide and related diuretics |
hepatic cirrhosis |
lactulose (> 30 mL per day), spironolactone (> 50 mg/day) |
osteoporosis |
bisphosphonates, calcitonin, teriparatide, vitamin D |
Parkinson's disease |
amantadine, anticholinergics, dopamine agonists, entacapone, levodopa with benserazide or carbidopa, monoamine oxidase type B inhibitors |
peptic ulcer |
antacids, bismuth subcitrate, H2 antagonists, misoprostol, proton pump inhibitors, sucralfate |
rheumatoid arthritis |
auranofin, hydroxychloroquine, immunosuppressants, penicillamine, sodium aurothiomalate, sulphasalazine, TNF-alpha antagonists |
thyroid disorder |
antithyroid drugs, thyroid hormone |
total score =
= SUM(points for all 20 chronic conditions)
Interpretation:
• minimum score: 0
• maximum score: 28
• The higher the score the greater the risk for hospitalization and for 1-year mortality.
Performance:
• The area under the ROC curve was 0.62 for prediction of 1-year mortality.